Financial incentives for COVID-19 vaccines in a rural low-resource setting: a cluster-randomized trial
We implemented a clustered randomized controlled trial with 6,963 residents in six rural Ghana districts to estimate the causal impact of financial incentives on coronavirus disease 2019 (COVID-19) vaccination uptake. Villages randomly received one of four video treatment arms: a placebo, a standard...
| Үндсэн зохиолчид: | , , , , , , , , , , |
|---|---|
| Формат: | Journal article |
| Хэл сонгох: | English |
| Хэвлэсэн: |
Springer Nature
2023
|
| _version_ | 1826312401150017536 |
|---|---|
| author | Duch, R Asiedu, E Nakamura, R Rouyard, T Mayol, A Barnett, A Roope, L Violato, M Sowah, D Kotlarz, P Clarke, P |
| author_facet | Duch, R Asiedu, E Nakamura, R Rouyard, T Mayol, A Barnett, A Roope, L Violato, M Sowah, D Kotlarz, P Clarke, P |
| author_sort | Duch, R |
| collection | OXFORD |
| description | We implemented a clustered randomized controlled trial with 6,963 residents in six rural Ghana districts to estimate the causal impact of financial incentives on coronavirus disease 2019 (COVID-19) vaccination uptake. Villages randomly received one of four video treatment arms: a placebo, a standard health message, a high cash incentive (60 Ghana cedis) and a low cash incentive (20 Ghana cedis). For the first co-primary outcome—COVID-19 vaccination intentions—non-vaccinated participants assigned to the cash incentive treatments had an average rate of 81% (1,733 of 2,168) compared to 71% (1,895 of 2,669) for those in the placebo treatment arm. For the other co-primary outcome of self-reported vaccinations 2 months after the initial intervention, the average rate for participants in the cash treatment was 3.5% higher than for participants in the placebo treatment (95% confidence interval (CI): 0.001, 6.9; P = 0.045): 40% (602 of 1,486) versus 36.3% (672 of 1,850). We also verified vaccination status of participants: in the cash treatment arm, 36.6% (355 of 1,058) of verified participants had at least one dose of the COVID-19 vaccine compared to 30.3% (439 of 1,544) for those in the placebo—a difference of 6.3% (95% CI: 2.4, 10.2; P = 0.001). For the intention and the vaccination outcomes, the low cash incentive (20 Ghana cedis) had a larger positive effect on COVID-19 vaccine uptake than the high cash incentive (60 Ghana cedis). Trial identifier: AEARCTR-0008775. |
| first_indexed | 2024-03-07T08:28:23Z |
| format | Journal article |
| id | oxford-uuid:e6f838a0-b442-4b47-93db-3f2ea3d83a6d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T08:28:23Z |
| publishDate | 2023 |
| publisher | Springer Nature |
| record_format | dspace |
| spelling | oxford-uuid:e6f838a0-b442-4b47-93db-3f2ea3d83a6d2024-02-26T09:25:46ZFinancial incentives for COVID-19 vaccines in a rural low-resource setting: a cluster-randomized trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:e6f838a0-b442-4b47-93db-3f2ea3d83a6dEnglishSymplectic ElementsSpringer Nature2023Duch, RAsiedu, ENakamura, RRouyard, TMayol, ABarnett, ARoope, LViolato, MSowah, DKotlarz, PClarke, PWe implemented a clustered randomized controlled trial with 6,963 residents in six rural Ghana districts to estimate the causal impact of financial incentives on coronavirus disease 2019 (COVID-19) vaccination uptake. Villages randomly received one of four video treatment arms: a placebo, a standard health message, a high cash incentive (60 Ghana cedis) and a low cash incentive (20 Ghana cedis). For the first co-primary outcome—COVID-19 vaccination intentions—non-vaccinated participants assigned to the cash incentive treatments had an average rate of 81% (1,733 of 2,168) compared to 71% (1,895 of 2,669) for those in the placebo treatment arm. For the other co-primary outcome of self-reported vaccinations 2 months after the initial intervention, the average rate for participants in the cash treatment was 3.5% higher than for participants in the placebo treatment (95% confidence interval (CI): 0.001, 6.9; P = 0.045): 40% (602 of 1,486) versus 36.3% (672 of 1,850). We also verified vaccination status of participants: in the cash treatment arm, 36.6% (355 of 1,058) of verified participants had at least one dose of the COVID-19 vaccine compared to 30.3% (439 of 1,544) for those in the placebo—a difference of 6.3% (95% CI: 2.4, 10.2; P = 0.001). For the intention and the vaccination outcomes, the low cash incentive (20 Ghana cedis) had a larger positive effect on COVID-19 vaccine uptake than the high cash incentive (60 Ghana cedis). Trial identifier: AEARCTR-0008775. |
| spellingShingle | Duch, R Asiedu, E Nakamura, R Rouyard, T Mayol, A Barnett, A Roope, L Violato, M Sowah, D Kotlarz, P Clarke, P Financial incentives for COVID-19 vaccines in a rural low-resource setting: a cluster-randomized trial |
| title | Financial incentives for COVID-19 vaccines in a rural low-resource setting: a cluster-randomized trial |
| title_full | Financial incentives for COVID-19 vaccines in a rural low-resource setting: a cluster-randomized trial |
| title_fullStr | Financial incentives for COVID-19 vaccines in a rural low-resource setting: a cluster-randomized trial |
| title_full_unstemmed | Financial incentives for COVID-19 vaccines in a rural low-resource setting: a cluster-randomized trial |
| title_short | Financial incentives for COVID-19 vaccines in a rural low-resource setting: a cluster-randomized trial |
| title_sort | financial incentives for covid 19 vaccines in a rural low resource setting a cluster randomized trial |
| work_keys_str_mv | AT duchr financialincentivesforcovid19vaccinesinarurallowresourcesettingaclusterrandomizedtrial AT asiedue financialincentivesforcovid19vaccinesinarurallowresourcesettingaclusterrandomizedtrial AT nakamurar financialincentivesforcovid19vaccinesinarurallowresourcesettingaclusterrandomizedtrial AT rouyardt financialincentivesforcovid19vaccinesinarurallowresourcesettingaclusterrandomizedtrial AT mayola financialincentivesforcovid19vaccinesinarurallowresourcesettingaclusterrandomizedtrial AT barnetta financialincentivesforcovid19vaccinesinarurallowresourcesettingaclusterrandomizedtrial AT roopel financialincentivesforcovid19vaccinesinarurallowresourcesettingaclusterrandomizedtrial AT violatom financialincentivesforcovid19vaccinesinarurallowresourcesettingaclusterrandomizedtrial AT sowahd financialincentivesforcovid19vaccinesinarurallowresourcesettingaclusterrandomizedtrial AT kotlarzp financialincentivesforcovid19vaccinesinarurallowresourcesettingaclusterrandomizedtrial AT clarkep financialincentivesforcovid19vaccinesinarurallowresourcesettingaclusterrandomizedtrial |